1. Home
  2. CRNX vs USAC Comparison

CRNX vs USAC Comparison

Compare CRNX & USAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crinetics Pharmaceuticals Inc.

CRNX

Crinetics Pharmaceuticals Inc.

HOLD

Current Price

$42.21

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

USAC

USA Compression Partners LP

HOLD

Current Price

$26.19

Market Cap

4.1B

Sector

Utilities

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRNX
USAC
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Natural Gas Distribution
Sector
Health Care
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.1B
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
CRNX
USAC
Price
$42.21
$26.19
Analyst Decision
Strong Buy
Hold
Analyst Count
8
3
Target Price
$76.75
$26.67
AVG Volume (30 Days)
1.3M
287.2K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
7.72%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,039,000.00
$698,365,000.00
Revenue This Year
$720.10
$33.35
Revenue Next Year
$184.67
$6.09
P/E Ratio
N/A
$31.25
Revenue Growth
N/A
19.51
52 Week Low
$25.83
$21.85
52 Week High
$57.99
$30.55

Technical Indicators

Market Signals
Indicator
CRNX
USAC
Relative Strength Index (RSI) 71.81 46.70
Support Level $38.68 $26.11
Resistance Level $44.89 $28.79
Average True Range (ATR) 1.71 0.94
MACD 0.74 0.06
Stochastic Oscillator 97.89 48.90

Price Performance

Historical Comparison
CRNX
USAC

About CRNX Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.

About USAC USA Compression Partners LP

USA Compression Partners LP provides compression services in the United States in terms of total compression fleet horsepower to customers relating to infrastructure applications, including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. It engineers, designs, operates, services, and repairs its compression units and maintains related support inventory and equipment. The company provides compression services throughout the U.S., including the Utica, Marcellus, Permian, Denver-Julesburg, Eagle Ford, Mississippi Lime, Granite Wash, Woodford, Barnett, and Haynesville.

Share on Social Networks: